Literature DB >> 1322242

Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.

K Münger1, M Scheffner, J M Huibregtse, P M Howley.   

Abstract

The HPVs associated with anogenital cancers encode two oncoproteins, E6 and E7. Both E6 and E7 can form specific complexes with tumour suppressor gene products. The E7 protein binds to the retinoblastoma tumour suppressor gene product pRB, with a preference for the underphosphorylated, "active" form of pRB. The E7 proteins derived from the "high risk" HPVs bind to pRB with a higher affinity than the E7 proteins from the "low risk" HPVs. The "high risk" HPV E6 proteins can associate with the p53 tumour suppressor protein. This interaction promotes the degradation of p53 in vitro, which presumably accounts for the very low levels of p53 in cervical carcinoma cell lines. The functional inactivation of pRB and p53 by the HPV oncoproteins E7 and E6, respectively, are likely to be important steps in cervical carcinogenesis, since mutations in the RB and p53 genes were detected in HPV negative but not HPV positive cervical carcinoma cell lines. Cytogenetic studies strongly suggest, however, that additional chromosomal changes may be necessary for carcinogenic progression of HPV induced anogenital lesions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322242

Source DB:  PubMed          Journal:  Cancer Surv        ISSN: 0261-2429


  71 in total

1.  PIG3V, an immortalized human vitiligo melanocyte cell line, expresses dilated endoplasmic reticulum.

Authors:  I C Le Poole; R E Boissy; R Sarangarajan; J Chen; J J Forristal; P Sheth; W Westerhof; G Babcock; P K Das; C B Saelinger
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-05       Impact factor: 2.416

2.  The interaction between human papillomavirus type 16 and FADD is mediated by a novel E6 binding domain.

Authors:  Sandy S Tungteakkhun; Maria Filippova; Jonathan W Neidigh; Nadja Fodor; Penelope J Duerksen-Hughes
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

3.  The SMC5/6 Complex Interacts with the Papillomavirus E2 Protein and Influences Maintenance of Viral Episomal DNA.

Authors:  Peris Bentley; Min Jie Alvin Tan; Alison A McBride; Elizabeth A White; Peter M Howley
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

4.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

Authors:  A Gualberto; K Aldape; K Kozakiewicz; T D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  Enumeration of the simian virus 40 early region elements necessary for human cell transformation.

Authors:  William C Hahn; Scott K Dessain; Mary W Brooks; Jessie E King; Brian Elenbaas; David M Sabatini; James A DeCaprio; Robert A Weinberg
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

Review 6.  The Role of the Gut Microbiome in Colorectal Cancer.

Authors:  Grace Y Chen
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

7.  Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame.

Authors:  S N Stacey; D Jordan; P J Snijders; M Mackett; J M Walboomers; J R Arrand
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

Review 8.  Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.

Authors:  Chuan-Ming Xie; Wenyi Wei; Yi Sun
Journal:  J Genet Genomics       Date:  2013-02-10       Impact factor: 4.275

9.  Adeno-associated virus type 2 induces apoptosis in human papillomavirus-infected cell lines but not in normal keratinocytes.

Authors:  Samina Alam; Craig Meyers
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

10.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.